Ronda E. Stryker Sells 200,000 Shares of Stryker Co. (NYSE:SYK) Stock

Stryker Co. (NYSE:SYK) Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares of the company’s stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Stryker Stock Performance

NYSE SYK opened at $380.87 on Friday. The stock has a market capitalization of $145.37 billion, a PE ratio of 49.08, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company’s 50 day simple moving average is $365.47 and its two-hundred day simple moving average is $374.30. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.50 EPS. Analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker’s payout ratio is 45.41%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. raised its holdings in shares of Stryker by 6.2% during the 3rd quarter. Principal Financial Group Inc. now owns 398,422 shares of the medical technology company’s stock valued at $143,934,000 after buying an additional 23,329 shares in the last quarter. Rempart Asset Management Inc. lifted its holdings in shares of Stryker by 5.0% in the 4th quarter. Rempart Asset Management Inc. now owns 49,496 shares of the medical technology company’s stock worth $17,821,000 after acquiring an additional 2,351 shares during the last quarter. ST Germain D J Co. Inc. boosted its stake in shares of Stryker by 14.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 2,362 shares of the medical technology company’s stock valued at $850,000 after purchasing an additional 300 shares in the last quarter. Sugarloaf Wealth Management LLC raised its position in Stryker by 11.2% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 496 shares of the medical technology company’s stock worth $179,000 after purchasing an additional 50 shares during the period. Finally, Tilia Fiduciary Partners Inc. lifted its stake in Stryker by 3.6% in the fourth quarter. Tilia Fiduciary Partners Inc. now owns 7,075 shares of the medical technology company’s stock worth $2,548,000 after purchasing an additional 243 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SYK. Sanford C. Bernstein set a $450.00 price target on Stryker in a report on Monday. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price target on shares of Stryker in a report on Friday, March 21st. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a report on Tuesday, March 4th. BTIG Research set a $403.00 target price on shares of Stryker and gave the company a “buy” rating in a research report on Monday, April 14th. Finally, Stifel Nicolaus lifted their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $427.05.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.